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Dietary sodium is thought to play a major role in the
pathogenesis of hypertension, hypervolemia, and mortality
in hemodialysis patients; hence, sodium restriction is almost
universally recommended. Since the evidence upon which to
base these assumptions is limited, we undertook a post-hoc
analysis of 1770 patients in the Hemodialysis Study with
available dietary, clinical, and laboratory information. Within
this cohort, 772 were men, 1113 black, and 786 diabetic, with
a mean age of 58 years and a median dietary sodium intake
of 2080mg/day. After case-mix adjustment, linear regression
modeling found that higher dietary sodium was associated
with a greater ultrafiltration requirement, caloric and protein
intake; sodium to calorie intake ratio was associated with a
greater ultrafiltration requirement; and sodium to potassium
ratio was associated with higher serum sodium. No indices
were associated with the pre-dialysis systolic blood pressure.
Cox regression modeling found that higher baseline dietary
sodium and the ratio of sodium to calorie or potassium
were each independently associated with greater all-cause
mortality. No association between a prescribed dietary
sodium restriction and mortality were found. Thus, higher
reported dietary sodium intake is independently associated
with greater mortality among prevalent hemodialysis
patients. Randomized trials will be necessary to determine
whether dietary sodium restriction improves survival.
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Sodium restriction has been a central tenet for management of
hemodialysis patients since renal replacement therapy first
became available. Total body sodium is a critical determinant
of extracellular volume, plasma volume, and blood pressure.1
Under conditions of health, sodium balance is tightly
regulated, principally through natriuresis.2 However, in oligo-
anuric hemodialysis subjects, renal sodium excretion is severely
impaired, and the hemodialysis procedure must provide for
requisite sodium and water removal.
Previous studies in hemodialysis subjects have suggested
that dietary salt restriction is associated with reduced inter-
dialytic weight gain (IDWG), lesser requirement for anti-
hypertensive medication, and ameliorative effects on left
ventricular hypertrophy.3–5 It has therefore been recom-
mended that hemodialysis patients carefully restrict sodium
intake,6 with the belief that this leads to improved volume
and blood pressure control, and ultimately survival. How-
ever, in peritoneal dialysis, there is evidence that lower dietary
sodium may actually be associated with higher mortality.7
One potential explanation for this finding is that, because
sodium and caloric intake are highly correlated,8 the fluid
homeostatic benefits of salt restriction are outweighed by
unintended concomitant nutritional compromise.
Overall, prior studies in hemodialysis patients have been
limited by small size, lack of prospectively collected data,
limited follow-up, and consideration of only surrogate end
points. To our knowledge, there has been no directed study of
the association between dietary sodium intake and mortality.
To address these limitations, we conducted a post-hoc analysis of
the Hemodialysis (HEMO) Study, a large-scale, prospective trial
with detailed dietary assessments. We examined the associations
of reported dietary sodium (diet-Na) intake with ultrafiltration
(UF) requirement, systolic blood pressure (SBP), nutritional
indices, and all-cause mortality. In an attempt to further
delineate the macronutrient-independent associations of diet-
ary sodium intake with all-cause mortality, we performed
analogous analyses considering sodium:calorie intake ratio
(Na:Cal) and sodium:potassium intake ratio (Na:K) as the
exposures of interest. Finally, we considered prescribed sodium
restriction to explore the potential clinical effectiveness of
advice regarding dietary sodium intake on outcomes.
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RESULTS
The primary cohort consisted of 1770 subjects; mean age was
58 (±14) years; 44% were men, 63% were black, and 44%
were diabetic (Table 1). Mean reported diet-Na was 2240
(±1050)mg/day, median was 2080 (interquartile range:
1490–2850)mg/day; mean Na:Cal was 1.46±0.53mg/kcal;
and mean Na:K was 1.50±0.80mg/mg (Figure 1). At baseline,
higher diet-Na was associated with younger age, male sex, non-
black race, older dialysis vintage, longer dialysis session length,
and absence of diabetes, ischemic heart disease, and oliguria.
Higher Na:Cal was associated with non-black race, diabetes,
and longer dialysis session length. Higher Na:K was associated
Table 1 | Baseline characteristics of the total study cohort and comparisons of daily dietary sodium intake (mg/day),
sodium:calorie intake ratio (mg/kcal), and sodium:potassium intake ratio (mg/mg) among subgroupsa
Mean reported dietary intake
N (%) Diet-Na (mg/day) P-value Na:Cal (mg/kcal) P-value Na:K (mg/mg) P-value
Age (years) o0.001 0.10 o0.001
o50 489 (27.6) 2597±1155 1.53±0.50 1.70±0.91
50–65 613 (34.6) 2131±944 1.46±0.50 1.49±0.80
465 668 (37.8) 2077±991 1.49±0.57 1.40±0.70
Sex o0.001 0.59 0.05
Male 772 (43.6) 2546±1132 1.50±0.52 1.56±0.83
Female 998 (56.4) 2002±908 1.48±0.53 1.48±0.78
Race o0.001 0.03 0.05
Black 1113 (62.9) 2170±1015 1.47±0.49 1.53±0.82
Non-black 657 (37.1) 2357±1089 1.52±0.58 1.47±0.77
Diabetes o0.001 0.001 0.002
Present 786 (44.4) 2123±1028 1.54±0.52 1.45±0.74
Absent 984 (55.6) 2333±1053 1.45±0.53 1.57±0.84
IHD 0.005 0.88 0.01
Present 692 (39.1) 2153±998 1.49±0.53 1.45±0.77
Absent 1078 (60.9) 2295±1074 1.49±053 1.55±0.82
CHF 0.51 0.06 0.06
None 1077 (60.8) 2257±1052 1.47±0.50 1.55±0.85
Mild 492 (27.8) 2231±1072 1.53±0.57 1.48±0.70
Mod/severe 201 (11.4) 2165±955 1.51±0.57 1.43±0.80
Vintage (months) 0.01 0.37 0.001
0–12 247 (13.9) 2156±1016 1.44±0.54 1.37±0.65
12–24 458 (25.9) 2174±1063 1.49±0.51 1.49±0.83
24–48 485 (27.4) 2207±996 1.51±0.56 1.49±0.69
448 580 (32.8) 2353±1081 1.49±0.51 1.62±0.91
Session length (minutes) o0.001 0.03 0.42
p180 528 (29.8) 2079±1024 1.44±0.52 1.47±0.78
181–209 377 (21.3) 2245±1069 1.51±0.60 1.55±0.89
210–239 572 (32.3) 2260±1035 1.50±0.52 1.53±0.84
X240 293 (16.6) 2483±1037 1.54±0.45 1.53±0.66
Access 0.002 0.04 0.45
AVG 1052 (59.4) 2181±1010 1.51±0.54 1.50±0.73
AVF 602 (34.0) 2360±1120 1.45±0.51 1.52±0.91
Catheter 116 (6.6) 2148±928 1.51±0.51 1.60±0.80
Urine outputb 0.003 0.39 0.48
Non-oliguric 236 (13.3) 2425±1173 1.52±0.49 1.48±0.64
Oliguric 1534 (86.7) 2211±1024 1.49±0.54 1.52±0.83
Flux group 0.99 0.16 0.22
High 882 (49.8) 2239±1038 1.47±0.51 1.49±0.76
Low 888 (50.2) 2240±1066 1.51±0.55 1.54±0.85
Kt/V group 0.59 0.26 0.42
High 884 (49.9) 2226±1054 1.50±0.51 1.53±0.80
Standard 886 (50.1) 2253±1040 1.48±0.55 1.50±0.81
Abbreviations: AVF, arteriovenous fistula; AVG, arteriovenous graft; CHF, congestive heart failure; diet-Na, daily sodium intake; IHD, ischemic heart disease; Na:Cal, daily dietary
sodium:calorie intake ratio; Na:K, daily dietary sodium:potassium intake ratio.
aP-value for global difference; significance testing was by t-test for dichotomous variables and analysis of variance for multilevel categorical variables.
bOliguria defined as residual urine output p200ml/day.
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with younger age, male sex, older dialysis vintage, and the
absence of diabetes and ischemic heart disease. The intra-class
correlation coefficients (95% confidence intervals (CIs)) within
subject over the course of follow-up were 0.38 (95% CI: 0.34,
0.41) for diet-Na, 0.48 (95% CI: 0.45, 0.51) for caloric intake,
and 0.34 (95% CI: 0.31, 0.37) for potassium intake.
Associations with nutritional indices, volume status, and
blood pressure
At baseline, higher diet-Na was modestly, but significantly,
correlated with height, post-dialysis weight, serum albumin,
and creatinine (Table 2). Upon multivariable adjustment,
these correlations were attenuated and no longer statistically
significant. Diet-Na was strongly correlated with daily caloric,
protein, and potassium intake. Again, these associations were
attenuated upon multivariable adjustment, after which only
an association with daily caloric intake remained significant.
Na:Cal was not associated with anthropometric measures,
or serum nutritional markers. It was modestly inversely
correlated with daily protein and potassium intake. Na:K was
not associated with anthropometric measures, or serum
nutritional markers (Supplementary Table S1 online); it was
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Figure 1 |Daily dietary sodium intake. Distribution of daily dietary sodium intake (mg/day; a), sodium:calorie intake ratio (mg/kcal; b),
sodium:potassium intake ratio (mg/mg; c), and prescribed dietary sodium intake (mg/day; d) at baseline.
Table 2 | Distribution of anthropometric variables, nutritional indices, and dietary intake parameters among the cohort, and
associations with daily dietary sodium intake (g/day) and sodium:calorie intake ratio (mg/kcal)
Correlation with diet-Na intake Correlation with Na:Cal intake ratio
Mean (s.d.) Unadjusteda Model 1b Model 2c Unadjusteda Model 1b Model 2c
Height (cm) 165.8 (10.2) 0.22* 0.06** 0.02 0.004 0.02 0.01
Post-HD wt (kg) 69.6 (14.9) 0.05*** 0.01 0.01 0.03 0.004 0.02
MAMC (cm) 24.3 (4.7) 0.02 0.03 0.04 0.01 0.02 0.03
TSFT (mm) 18.6 (13.0) 0.10* 0.02 0.03 0.03 0.01 0.01
Alb (g/dl) 3.8 (0.4) 0.06** 0.01 0.02 0.01 0.01 0.02
Cr (mg/dl) 10.3 (2.9) 0.12* 0.01 0.001 0.04 0.01 0.003
Caloric intake (kcal/day) 1523 (547) 0.68* 0.63* 0.40* — — —
Protein intake (g/day) 62.7 (23.1) 0.50* 0.45* 0.04 0.10* 0.11* 0.12*
K intake (mg/day) 1612 (658) 0.46* 0.43* 0.03 0.10* 0.11* 0.04***
Abbreviations: Alb, serum albumin; Cr, pre-dialysis serum creatinine; diet-Na, daily dietary sodium intake; HD, hemodialysis; HEMO Study, Hemodialysis Study; K, potassium;
MAMC, mid-arm muscle circumference; Na:Cal, daily dietary sodium:calorie intake ratio; TSFT, triceps skin-fold thickness.
aUnadjusted associations estimated by Pearson’s correlation.
bModel 1 estimates represent partial correlation coefficients based on linear regression models adjusted for age, sex, race (black vs. non-black), HEMO Study Kt/V and flux
group assignments, post-dialysis weight, sex-by-weight cross-product terms, access (fistula, graft, and catheter), congestive heart failure status (none, mild, and moderate/
severe), the presence/absence of diabetes and ischemic heart disease (post-dialysis weight and sex-by-weight cross-product terms not included as predictors in models for
which post-dialysis weight was the response variable).
cModel 2 adjusted as per Model 1 as well as for serum sodium, albumin (p3.5, 3.5–4.0, and44.0 g/dl), serum creatinine, ultrafiltration requirement, caloric intake, and protein
intake (individual covariates were not included as predictors in models for which they were the response parameter).
*Pp0.001.
**Pp0.01.
***Pp0.05.
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modestly associated with daily caloric intake and inversely
associated with protein intake. Longitudinal mixed-linear
models demonstrated no association between baseline diet-
Na, Na:Cal, and Na:K, and subsequent changes in nutritional
parameters over time (data not shown).
Higher diet-Na and Na:Cal were associated with increased
UF requirement, although the magnitudes of these associa-
tions were small (Table 3). Diet-Na and Na:Cal demonstrated
modest associations with pre-dialysis SBP, which variably
achieved statistical significance depending on the modeling
strategy used. Neither diet-Na nor Na:Cal was associated with
serum sodium. Na:K was modestly associated with increased
serum sodium, but not with UF requirement or pre-dialysis
SBP (Supplementary Table S2 online).
Associations with mortality
Overall, participants contributed 4378 patient-years of at-risk
time, during which 750 deaths occurred; median follow-up
time was 2.1 years.
Reported diet-Na was initially considered as a restricted
cubic spline with knots at 1500, 2000, and 2500mg/day; the
observed association with log mortality hazard was essentially
linear (Supplementary Figure S1 online). Thus, reported diet-
Na was considered as a linear term in all subsequent analyses.
On unadjusted analysis, baseline diet-Na was not associated
with all-cause mortality. However, diet-Na was associated with
differences in important prognostic variables. When case-mix
differences were accounted for through multivariable adjust-
ment, a potent and significant association was observed; this
was further accentuated upon additional adjustment for
differences in nutritional parameters (Figure 2). Across
quartiles of diet-Na, there was an incremental association
with greater adjusted risk of mortality (Figure 3a). Considered
in both linear and categorical forms, the association between
diet-Na and mortality was similar regardless of body weight
(P-interaction 40.10 for all models).
Baseline Na:Cal was potently associated with all-cause
mortality on unadjusted analysis. This association remained
largely unchanged upon multivariable adjustment (Figure 2).
Categorical analysis again revealed an incrementally greater
adjusted mortality risk across quartiles of Na:Cal (Figure 3b).
The pattern of association between Na:K and mortality was
similar to that seen for diet-Na (Figures 2 and 3c). For all
metrics of sodium intake, observed estimates were essentially
unchanged when reported caloric and protein intake were
forced into Model 2 (only protein intake was forced into
Na:Cal analyses to avoid collinearity).
Prescribed sodium restriction
Median prescribed sodium restriction was 2000 (interquartile
range: 2000–3000)mg/day (Figure 1d). At baseline, more liberal
Table 3 | Distribution of UF requirement, SBP, and serum Na, and associations with daily dietary sodium intake (g/day) and
sodium:calorie intake ratio (mg/kcal)a
Association with diet-Na intake per g/day Association with Na:Cal intake ratio per mg/kcal
Mean (s.d.) Unadjusted Model 1b Model 2c Unadjusted Model 1b Model 2c
UF requirement (l) 2.9 (1.3) 0.14* 0.06*** 0.09*** 0.17** 0.10 0.13***
SBP (mmHg) 152 (26) 0.13 0.61 1.58*** 2.48*** 1.98 1.65
Serum Na (mEq/l) 138.3 (3.9) 0.16 0.15 0.22 0.05 0.23 0.29
Abbreviations: Diet-Na, daily dietary sodium intake; HEMO Study, Hemodialysis Study; Na, sodium; Na:Cal, daily dietary sodium:calorie intake ratio; SBP, pre-dialysis systolic
blood pressure; UF, ultrafiltration.
aAssociations estimated by linear regression models and expressed as adjusted mean difference in response parameter per 1000mg/day increment in diet-Na or 1mg/kcal/
day increment in Na:Cal.
bModel 1 adjusted for age, sex, race (black vs. non-black), HEMO Study Kt/V and flux group assignments, post-dialysis weight, sex-by-weight cross-product terms, access
(fistula, graft, and catheter), congestive heart failure status (none, mild, and moderate/severe), the presence/absence of diabetes, and ischemic heart disease.
cModel 2 adjusted as per Model 1 as well as for serum sodium, albumin (p3.5, 3.5–4.0, and 44.0 g/dl), serum creatinine, UF requirement, caloric intake, and protein intake.
*Pp0.001.
**Pp0.01.
***Pp0.05.
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Figure 2 |Hazard ratios (HRs) (95% confidence intervals (CIs))
between measures of daily sodium intake and all-cause
mortality. Sodium was considered as total intake (mg/day),
sodium:calorie intake ratio (Na:Cal; mg/kcal), and
sodium:potassium intake ratio (Na:K; mg/mg). Unadjusted
estimates are indicated by circles. Estimates from Model 1
(squares) were adjusted for age, sex, race (black vs. non-black),
HEMO Study Kt/V and flux group assignments, post-dialysis
weight, sex-by-post-weight cross-product terms, access (fistula,
graft, and catheter), congestive heart failure status (none, mild,
and moderate/severe), the presence/absence of diabetes and
ischemic heart disease, urine volume (p200 and 4200ml/day),
and dialysis session length (p180, 181–209, 210–239, and
X240min). Estimates from Model 2 (triangles) were additionally
adjusted for serum sodium, albumin (p3.5, 3.5–4.0, and44.0 g/dl),
phosphorus, creatinine, and ultrafiltration requirement.
All models were stratified on clinical center.
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prescribed sodium restriction (42 vs. p2 g/day) was asso-
ciated with male sex, non-black race, congestive heart failure,
non-oliguria, longer dialysis session length, greater height,
weight, and mid-arm muscle circumference, lower triceps skin-
fold thickness, and greater reported daily caloric, protein, and
potassium intake (Supplementary Table S3 online).
At baseline, participants with more liberal (vs. restrictive)
prescribed sodium restriction had higher mean reported diet-
Na (2370±1070 vs. 2170±1030mg/day; Po0.001), but the
difference was modest. More liberal prescribed sodium
restriction was independently associated with lower UF
requirement and serum sodium (adjusted mean differences
per Model 1: 0.17 l (P¼ 0.01) and 0.47mEq/l (P¼ 0.02),
respectively), but not with pre-dialysis SBP.
On unadjusted analysis, intensity of baseline prescribed
sodium restriction was not associated with all-cause mortal-
ity (Figure 4). Estimates were qualitatively unchanged upon
multivariable adjustment. When marginal structural analysis
was used to account for potential time-dependent confound-
ing, no association between intensity of prescribed sodium
restriction and mortality was observed: hazard ratio (95%
CI) for liberal (vs. restrictive) was 1.03 (0.86–1.23; P¼ 0.74).
DISCUSSION
To our knowledge, this is the first study to directly examine
the association of indices of dietary sodium intake with
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Figure 3 |Association between quartiles of dietary sodium intake and mortality. Hazard ratios (95% confidence intervals (CIs)) for all-
cause mortality according to quartiles (Q; referent Q1) of reported daily dietary sodium intake (mg/day; a), daily sodium:calorie intake ratio
(mg/kcal; b), and sodium:potassium intake ratio (mg/mg; c). Estimates from Model 1 were adjusted for age, sex, race (black vs. non-black),
HEMO Study Kt/V and flux group assignments, post-dialysis weight, sex-by-post-weight cross-product terms, access (fistula, graft, and
catheter), congestive heart failure status (none, mild, and moderate/severe), the presence/absence of diabetes and ischemic heart disease,
urine volume (p200 and4200ml/day), and dialysis session length (p180, 181–209, 210–239, andX240min). Estimates from Model 2 were
additionally adjusted for serum sodium, albumin (p3.5, 3.5–4.0, and44.0 g/dl), phosphorus, creatinine, and ultrafiltration requirement. All
models were stratified on clinical center.
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Figure 4 |Association between prescribed sodium restriction
and mortality. Associations between liberal (42 g/day) and
restrictive (p2 g/day; referent group; hazard ratio (HR)¼ 1, not
shown) prescribed sodium restriction and all-cause mortality.
Estimates from Model 1 were adjusted for age, sex, race (black vs.
non-black), HEMO Study Kt/V and flux group assignments, post-
dialysis weight, sex-by-post-weight cross-product terms, access
(fistula, graft, and catheter), congestive heart failure status (none,
mild, and moderate/severe), the presence/absence of diabetes
and ischemic heart disease, urine volume (p200 and4200ml/day),
and dialysis session length (p180, 181–209, 210–239, and
X240min). Estimates from Model 2 were additionally adjusted
for serum sodium, albumin (p3.5, 3.5–4.0, and 44.0 g/dl),
phosphorus, creatinine, and ultrafiltration requirement. All models
were stratified on clinical center. CI, confidence interval.
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mortality in the hemodialysis population. Moreover, it is the
first to examine the association of diet-Na with IDWG and
SBP in a large, prospective and well-characterized cohort.
The primary findings of our study are that greater reported
sodium intake is independently associated with an increased
risk of death and modestly greater UF requirement, but bore
no consistent independent association with pre-dialysis SBP.
More restrictive (vs. liberal) prescribed diet-Na is associated
with modestly lower reported sodium intake, but not with
mortality, UF requirement, macronutrient intake, or SBP.
An association between diet-Na and hypertension in the
general population has been well established,9 and reductions
in diet-Na are commensurately associated with blood pres-
sure reductions in hypertensive, pre-hypertensive, and normo-
tensive patients.10 Dietary sodium restriction (o2 g/day;
o88mmol/day) has long been championed as an important
target in patients with end-stage renal disease,6 with the
belief that adherence would lead to meaningful reductions
in IDWG, blood pressure, and mortality. Prior studies in
hemodialysis patients have demonstrated improvements
in blood pressure control with dietary sodium restriction
alone,11 or combined with either reduced dialysate so-
dium12,13 or intensive UF.3 However, small sample size, lack
of dietary sodium measurements, and short follow-up limit
the utility of these findings. In this large, well-characterized
cohort, we did not detect a consistent independent asso-
ciation of reported diet Na, Na:Cal, Na:K, or prescribed
sodium restriction with SBP. However, it should be noted
that hemodynamic effects of sodium restriction may only
become manifest in the setting of concurrent dry-weight
reductions, which were not prescriptively performed in the
HEMO Study.14
Prior work also suggests that greater sodium intake is
associated with greater IDWG.3,11 We found statistically
significant associations between higher reported diet Na,
Na:Cal (but not Na:K), and greater UF requirement.
However, the clinical implications of these findings may be
limited considering the small magnitude of association
(90ml requisite ultrafiltrate per 1000mg increment in diet-
Na intake; 130ml ultrafiltrate per 1mg/kcal increment in
Na:Cal). It is possible that in HD patients other sources of
sodium (e.g., ‘loading’ from relatively hypernatremic dialy-
sate), non-osmotically mediated thirst (e.g., from transient
intravascular hypovolemia following dialysis), or habitual
drinking may have a greater role in determining IDWG and
pre-dialysis SBP than previously recognized.
It is interesting to note that unadjusted analyses failed to
demonstrate an association between diet-Na (and dietary
Na:K ratio) and mortality owing to extensive confounding
(i.e., healthier patients tended to consume more sodium);
however, when such differences were adjusted for (Model 1),
a potent and independent association was observed. We
estimated the diet-Na–mortality association without (Model
1) and with (Model 2) adjustment for nutritional indices.
The former may more accurately represent the effects of diet-
Na under prevailing clinical circumstances, where sodium
intake is obligatorily linked to caloric intake and nutritional
status. The latter may better estimate the therapeutic
potential of sodium curtailment under a (currently hypothe-
tical) paradigm where diet-Na can be manipulated without
attendant nutritional compromise. The fact that the diet-
Na–mortality association was further potentiated upon
adjustment for nutritional parameters (Model 2) suggests
that, at present, the beneficial effects of diet-Na restriction are
partially offset by unintended nutritional sequelae. Na:Cal
analyses provide complementary information, essentially
estimating the association between a one-unit increment in
diet-Na with caloric intake held constant. However, inter-
pretation of Na:Cal estimates must consider that a higher
ratio can also reflect lower caloric intake at constant sodium
intake. Na:K estimates were chosen as another means to
standardize diet-Na without incurring this interpretation
difficulty. It is notable that for each of these three metrics we
observed potent, significant, and dose-dependent associa-
tions upon case-mix adjustment, which in turn provides
reassurance that greater sodium intake is associated with
greater mortality risk.
Assuming that the diet-Na–mortality association is causal,
enthusiasm regarding clinical application must be tempered.
Analyses of prescribed sodium restriction, which better assess
clinical effectiveness (vs. those of reported diet-Na, which
point toward efficacy), did not find any association between
the degree of prescribed sodium restriction and improvements
in UF requirement, SBP, or mortality. Similarly, this stems
from poor adherence to prescribed sodium restriction, as
evidenced by the fact that mean diet-Na was only 200mg/day
lower among patients prescribed restrictive vs. liberal sodium
restrictions. It should be noted that our ability to detect
associations between intensity of prescribed dietary sodium
restriction and outcomes was limited by the fact that nearly all
patients in the study were prescribed some dietary sodium
restriction, and the range of prescribed limits was quite
constrained (effectively, we studied threshold of 2 vs. 3–4 g/day).
In this light, it is important that findings not be extrapolated
to suggest that liberal sodium restriction thresholds, beyond
the range studied, are safe. It is worth noting that subjects
with significant residual renal function (urea clearance
41.5ml/min/35 l urea) were excluded from participation in
the HEMO Study. It is possible that those individuals may be
better able to excrete excess sodium and thus be less sus-
ceptible to associated sequelae. Caution must therefore be
applied before generalizing results from the present analyses
to individuals with significant residual function.
Despite meticulous collection of prospective data in the
setting of a randomized clinical trial, there are limitations of
our study that deserve mention. The potential for exposure
misclassification requires careful consideration. Several studies
have questioned the utility of dietary recall in accurately
assessing true dietary sodium intake (r¼ 0.30–0.61),15–18
compared with 24 h urine sodium excretion as a gold standard.
For obvious reasons, urine collections would not provide
accurate diet-Na assessments in oligo-anuric subjects. The fact
Kidney International (2012) 82, 204–211 209
FR Mc Causland et al.: Dietary sodium and mortality in hemodialysis o r ig ina l a r t i c l e
that the magnitude of the association between reported diet-
Na intake and UF requirement we observed was consistent
with those reported in the literature3,11 offers a modicum of
reassurance that exposure misclassification was not untoward.
Moreover, inasmuch as random measurement error should
bias toward the null, our estimates should be conservative and
represent lower bounds on true biological associations. As with
all observational studies, the possibility of residual confound-
ing based on variables not considered (and for prescribed
sodium restriction, confounding by indication), or due to
incomplete adjustment of those that were considered, remains.
Finally, known differences between clinical trial participants
and the general hemodialysis population may limit the
generalizability of our findings.
In conclusion, higher reported dietary sodium, whether
expressed as raw intake, in proportion to caloric intake, or in
proportion to potassium intake, was associated with greater
mortality in prevalent hemodialysis subjects. Randomized
trials are warranted to determine whether dietary sodium
restriction, particularly if accomplished without decrement in
overall caloric intake, improves survival.
MATERIALS AND METHODS
Study design and population
The study was deemed exempt by the Partners Healthcare
Institutional Review Board. All data were abstracted from the
HEMO Study with the permission of the National Institute of
Diabetic and Digestive and Kidney diseases. The design of the
HEMO Study has been previously reported.19,20 Briefly, HEMO was
a prospective, multicenter, randomized clinical trial of standard/
high dialysis dose and low/high flux membranes among prevalent
adult subjects receiving thrice-weekly in-center hemodialysis.
Exclusion criteria included a baseline serum albumin o2.6 g/dl,
residual urea clearance of X1.5ml/min/35 l of urea distribution
volume, inability to consistently achieve an equilibrated Kt/V of
41.3, or the presence of end-stage comorbid conditions. Of the
1846 HEMO Study participants, we excluded those who did not
survive or were censored before the start of at-risk time (n¼ 76);
our final cohort consisted of 1770 individuals.
Exposures and outcomes
The primary exposures of interest were reported and prescribed
diet-Na intake, Na:Cal intake ratio, and Na:K intake ratio. Reported
dietary intake was assessed from 2-day diet diary assisted recalls.
Recall was performed on one dialysis and one non-dialysis day
(most often on consecutive days) at annual intervals. A trained study
dietitian entered the data into customized versions of the
Nutritionist IV (version 4.0a; March 1995–July 1999) or Nutritionist
V (versions 2.0h to 2.1h; August 1999–December 2001) software.
Dietary prescriptions were provided by the local dialysis center
dietitian, and were not influenced by HEMO Study dietitians, except
in the following circumstances: normalized protein catabolic rate
o1 g/kg/day; caloric intake o28 kcal/kg/day; and persistent decline
in serum albumin or unintentional weight loss. In these instances,
dietary counseling was provided, and, if insufficient, supplements
were recommended. HEMO Study dietitians were not involved in
diet-Na prescriptions.
The primary outcome was time to death from any cause. At-risk
time began on post-randomization day 90, to enable capture of
dietary recall data that lagged after randomization. Subjects were
followed up until censoring (transplant, transfer, or change in
modality; n¼ 335), death (n¼ 750), or study completion (31
December 2001; n¼ 685). Secondary outcomes included the
associations with UF requirement, pre-dialysis SBP, and other
biochemical, dietary, and anthropometric parameters.
Study data
In accordance with the HEMO protocol, all study data were obtained
via subject interview, chart review, and self-reported questionnaires.
Demographic data including sex, race, age, and vintage were
recorded at baseline and updated annually. Remaining variables of
interest were recorded at baseline and at scheduled intervals during
follow-up. These included diabetes mellitus, ischemic heart disease,
and congestive heart failure (annually); dialysis treatment param-
eters and hemodynamic parameters (monthly); mid-arm circumfer-
ence and triceps skin-fold thickness (annually; mid-arm muscle
circumference was calculated as arm circumferencep triceps skin-
fold thickness; both in cm); and laboratory (6 weekly) and prescribed
nutritional restrictions (biannually). Comorbidities were graded on
the Index of Coexisting Disease (ICED) scale; analytically, these were
dichotomized (0 if ICED score¼ 0; 1 if ICED score X1) except for
congestive heart failure (0 if ICED score¼ 0; 1 if ICED score¼ 1; 2 if
ICED score X2).21
Statistical analysis
Continuous variables were examined graphically and recorded as
means (±s.d.) for normally distributed data, or medians (with
interquartile ranges) for non-normally distributed data. Compar-
isons were made using t-tests or Wilcoxon’s rank-sum tests, as
appropriate. Categorical variables were examined by frequency
distribution, recorded as proportions, and comparisons made using
the w2-test.
Exposure variables and covariates were considered as the most
proximate value preceding at-risk time. The associations between
dietary sodium indices and covariates were examined by Pearson’s
correlation and by linear regression models (with varying degrees
of multivariable adjustment as described below). For nutritional
response variables, estimates were presented as partial correlation
coefficients (which are independent of the scale of the predictor or
response parameters) to facilitate comparison of the associations
across metrics of dietary sodium and across response parameters.
For UF requirement, SBP, and serum sodium, these were expressed
as b coefficients to facilitate clinical interpretation.
The associations between dietary sodium and mortality were
examined by proportional hazards regression. All survival models
were stratified on clinical center in order to minimize any potential
center effect. Eligible covariates for model inclusion were those that
demonstrated significant or near-significant association with
mortality (Po0.2) on bivariable analysis. HEMO Study flux and
Kt/V assignment were forced into the model, as this was a post-hoc
analysis of a randomized controlled trial. (Effect modification on the
basis of HEMO Study flux and Kt/V assignments was examined for
(separately) and excluded.) Two separate multivariable adjusted
models were fit. Model 1 included covariate terms for eligible
demographic, comorbidity, and dialysis-related variables (except UF
requirement) that were unlikely to serve as intermediates in causal
pathways between sodium intake and mortality. Model 2 addition-
ally included eligible covariates related to dietary intake, nutritional
adequacy, and UF requirement that might serve as intermediates on
some causal pathways.
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Because the prognostic significance of body size may differ
according to gender, two-way sex-by-dry weight cross-product
terms were included in all multivariable models. Effect modification
on the basis of body weight was tested for (via likelihood ratio
testing) by comparing nested models that did and did not contain
two-way sodium-by-weight interaction terms.
The linearity assumption for continuous variables was tested by
graphical examination of Martingale residual plots and by
comparative model fit diagnostics using Akaike’s information
criterion. The proportionality assumption was tested by scaled
Schoenfeld residual testing.
Time-updated marginal structural models were adjusted for the
same variables as Model 2, through application of stabilized
probability of exposure and censoring weights, as previously
described.22–26 Nominal two-sided P-values ofo0.05 were considered
statistically significant. Analyses were performed using STATA 10.0MP
(College Station, TX).
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